Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines', 31 January-2 February 2006, IAVI, New York, USA

AIDS

Volumn 21, Issue 4, 2007, Pages 539-546

  Ackland, Jim ^a   Allen, Susan ^b   Barth Jones, Daniel ^c   Birx, Deborah ^d   Chomba, Elwyn ^e   Churchyard, Gavin ^f   Duerr, Ann ^g   Jin, Shuigao ^h   Johnston, Margaret ⁱ   Fast, Patricia E ^j   Fix, Alan ⁱ   Foulkes, Mary ^k   Follmann, Dean ⁱ   Hutubessy, Raymond ^l   Malone, Siobhan ^m   Gray, Ronald ⁿ   Indrayan, Abhay ^o   Levin, Jonathan ^p   Mathieson, Bonnie J ^q   Mastro, Timothy D ^r   McNeil, John ⁱ   Osmanov, Saladin ^l   Pitisuttithum, Punnee ^s   Peters, Barry ^t   Karita, Etienne ^u   Robertson, Michael N ^v   Ramakrishnan, R ^w   Rees, Helen ^x   Rida, Wasima ^y   Ruan, Yuhua ^z   Sandström, Eric ^aa   Schmidt, Claudia ^j   Smith, Peter ^ab   Self, Steven ^ac   Thiry, Georges ^ad   Wasserheit, Judith ^ae   Priddy, Frances ^af   Thior, Ibou ^ag   Warren, Mitchell ^ah   Cooper, David ^ai   Kaleebu, Pontiano ^aj   Macklin, Ruth ^ak   Tangwa, Godfrey ^al   more..

^a Global BioSolutions   (Australia)

^b EMORY UNIVERSITY   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e Zambia UAB HIV Research Project   (Zambia)

^f Ernest Oppenheimer Hospital   (South Africa)

^g Scientific Support Unit   (United States)

^h CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

ⁱ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^j INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^k CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^l WORLD HEALTH ORGANIZATION   (Switzerland)

^m BILL AND MELINDA GATES FOUNDATION   (United States)

ⁿ JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^o UNIVERSITY COLLEGE OF MEDICAL SCIENCES   (India)

^p SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^q OAR HIV/AIDS Vaccine Coordinating Committee   (United States)

^r CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^s MAHIDOL UNIVERSITY   (Thailand)

^t ST THOMAS HOSPITAL   (United Kingdom)

^u Projet San Francisco   (Rwanda)

^v MERCK RESEARCH LABORATORIES   (United States)

^w National Institute of Epidemiology   (India)

^x UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^y Statistics Collaborative   (United States)

^z CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^aa KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^ab LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^ac Statistical Center for HIV/AIDS Research and Prevention   (United States)

^ad Karolinska University Hospital ^*  (France)

^ae HIV Vaccine Trials Network   (United States)

^af EMORY UNIVERSITY   (United States)

^ag BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^ah AIDS Vaccine Advocacy Coalition   (United States)

^ai UNIVERSITY OF NEW SOUTH WALES   (Australia)

^aj UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^ak ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^al UNIVERSITY OF YAOUNDÉ I   (Cameroon)

more..

Author keywords

Clinical trial design; HIV vaccines; Phase IIB trials; Proof of concept trials; Test of concept trials; Vaccine efficacy

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; CONSULTATION; DRUG EFFICACY; DRUG SAFETY; ETHICS; FOLLOW UP; GOVERNMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; UNITED STATES; WORLD HEALTH ORGANIZATION;

AIDS VACCINES; CLINICAL TRIALS, PHASE II; EVALUATION STUDIES; HIV INFECTIONS; HUMANS; INTERNATIONAL COOPERATION; RESEARCH DESIGN;

EID: 33847016909     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328011a0c9     Document Type: Review

References (9)

1. World Health Organization. Guidelines on clinical evaluation of vaccines: regulatory expectations. WHO technical report series 2004, no. 924. Geneva, World Health Organization; 2004.
2. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364:1757-1765.
3. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al., for the Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347:1645-1651.
4. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia. Obstet Gynecol 2006; 107:18-27.
5. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multi-centre phase II efficacy trial. Lancet Oncol 2005; 6:271-278.
6. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, et al. Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomized controlled trial. Lancet 2004; 364:1411-1420.
7. Follmann D, Duerr A, Tabet S, Gilbert P, Moodie Z, Fast P, et al. Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop. J Acqui Immune Defic Sydr 2007; 44:49-60.
8. Rida W, Fast P, Hoff R, Fleming T. Intermediate-size trials for the evaluation of HIV vaccine candidate: a workshop summary. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:195-203.
9. Lie R, Emmanuel E, Grady C. Circumcision and HIV prevention research: an ethical analysis. Lancet 2006; 368:522-525.